Martin Früh

11.0k total citations · 3 hit papers
106 papers, 4.0k citations indexed

About

Martin Früh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Martin Früh has authored 106 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 77 papers in Pulmonary and Respiratory Medicine and 17 papers in Molecular Biology. Recurrent topics in Martin Früh's work include Lung Cancer Treatments and Mutations (66 papers), Lung Cancer Research Studies (35 papers) and Lung Cancer Diagnosis and Treatment (22 papers). Martin Früh is often cited by papers focused on Lung Cancer Treatments and Mutations (66 papers), Lung Cancer Research Studies (35 papers) and Lung Cancer Diagnosis and Treatment (22 papers). Martin Früh collaborates with scholars based in Switzerland, Germany and Spain. Martin Früh's co-authors include Sabine Schmid, Enriqueta Felip, Lukas Flatz, Stefan Diem, Wolfram Jochum, Solange Peters, Arnoud J. Templeton, Diana Born, Sanjay Popat and Dirk De Ruysscher and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Martin Früh

102 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

2017 690 citations Stefan Diem, Sabine Schmid et al. Lung Cancer profile →
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2013 458 citations Martin Früh, Dirk De Ruysscher et al. Annals of Oncology profile →
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

2021 321 citations Martin Früh, Benjamin Besse et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Martin Früh

Since Specialization

Citations

This map shows the geographic impact of Martin Früh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Früh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Früh more than expected).

Fields of papers citing papers by Martin Früh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Früh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Früh. The network helps show where Martin Früh may publish in the future.

Co-authorship network of co-authors of Martin Früh

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Früh. A scholar is included among the top collaborators of Martin Früh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Früh. Martin Früh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment 2024 ·JTO Clinical and Research Reports ·Sabine Schmid, (unknown), (unknown), (unknown), Sacha I. Rothschild, Laura Boos, (unknown), (unknown), Christian Britschgi, Yannis Metaxas, Michael Mark, Patrizia Froesch, Wolf-Dieter Janthur, (unknown), Christine Waibel, (unknown), Martin Früh, Laetitia Mauti	2
2	Prolonged Response to Afatinib and Crizotinib in a Rare Case of EGFR-, HER2-, MET- and ROS1-Alterated Lung Adenocarcinoma 2024 ·International Journal of Molecular Sciences ·(unknown), Martin Früh, (unknown), (unknown), Wolfram Jochum, (unknown)	1
3	Unraveling the chicken T cell repertoire with enhanced genome annotation 2024 ·Frontiers in Immunology ·(unknown), Martin Früh, Benedikt B. Kaufer, Thomas Göbel	2
4	First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. 2023 ·Journal of Clinical Oncology ·Michael Mark, Patrizia Froesch, (unknown), Sacha I. Rothschild, Alfredo Addeo, Christoph Ackermann, (unknown), Martina Schneider, Karin Ribi, (unknown), Sara Bastian, (unknown), Markus Joerger, Martin Früh	0
5	Non-pharmaceutical interventions to optimize cancer immunotherapy 2023 ·OncoImmunology ·Maximilian Boesch, Florent Baty, Frank Rassouli, Tobias Kowatsch, Markus Joerger, Martin Früh, Martin Brutsche	5
6	A Literature Review of Racial Disparities in Prostate Cancer Research 2023 ·Current Oncology ·(unknown), (unknown), (unknown), (unknown), Daniel Taussky, (unknown), Martin Früh	0
7	Sotorasib Shows Intracranial Activity in Patients with <b><i>KRAS G12C-</i></b>Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Martin Früh, Sabine Schmid	13
8	Unusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Joachim Müller, Martin Früh	0
9	Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study 2022 ·ESMO Open ·Michael Mark, Sylvie Rusakiewicz, Martin Früh, Stefanie Hayoz, Federica Grosso, Miklos Pless, Paolo Andrea Zucali, Giovanni Luca Ceresoli, Antonio Maconi, Martina Schneider, Patrizia Froesch, (unknown), Fabrizio Benedetti, Julien Dagher, Lana E. Kandalaft, Roger von Moos, (unknown), Sabine Schmid, Yannis Metaxas	5
10	Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study 2022 ·Lung Cancer ·Alfredo Addeo, Sacha I. Rothschild, (unknown), Martina Schneider, Christine Waibel, Simon Haefliger, Michael Mark, Eugenio Fernández, Nicolas Mach, Laetitia Mauti, Philip Jermann, Ilaria Alborelli, Byron Calgua, Spasenija Savic-Prince, Markus Joerger, Martin Früh	13
11	1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial 2020 ·Annals of Oncology ·Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet, (unknown), Daniel Betticher, Adrienne Bettini, Martin Früh, Markus Joerger, Christian Britschgi, Solange Peters, Michael Mark, Adrian F. Ochsenbein, (unknown), Christine Waibel, Nicolas Mach, Michel González, Patrizia Froesch, Gilles Godar, Corinne Rusterholz, Miklos Pless	11
12	Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts 2020 ·Lung Cancer ·Martin Früh, Cédric Panje, Martin Reck, Fiona Blackhall, Raffaele Califano, Federico Cappuzzo, Benjamin Besse, Silvia Novello, Pilar Garrido, Enriqueta Felip, Mary O’Brien, Luis Paz Ares, Filippo de Marinis, Virginie Westeel, Dirk De Ruysscher, Paul Martin Putora	11
13	Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment 2018 ·Cancer Management and Research ·Stefan Diem, Mirjam Fässler, Omar Hasan Ali, Marco Siano, Rebekka Niederer, Fiamma Berner, (unknown), Christoph Ackermann, Sabine Schmid, Sabine Güsewell, Martin Früh, Lukas Flatz	2
14	Immune checkpoint inhibitors and small cell lung cancer: what’s new? 2018 ·Journal of Thoracic Disease ·Sabine Schmid, Martin Früh	14
15	Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study 2016 ·Lung Cancer ·(unknown), Ladina Joos, René Warschkow, André Dutly, S.M. Ess, Felicitas Hitz, Martin Früh, Martin Brutsche, Florent Baty, Stephan Krähenbühl, Thomas Cerny, Markus Joerger	4
16	SUV<sub>max</sub> and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer 2016 ·Oncology Research and Treatment ·Paul Martin Putora, (unknown), Markus Glatzer, Regulo Rodriguez, Joachim Müller, Florent Baty, Martin Früh	9
17	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort 2015 ·Annals of Oncology ·Julien Mazières, Fabrice Barlési, Thomas Filleron, Benjamin Besse, I. Monnet, Michèle Beau‐Faller, Solange Peters, Éric Dansin, Martin Früh, Miklos Pless, Rafael Rosell, Marie Wislez, P. Fournel, Virginie Westeel, Federico Cappuzzo, Alexis B. Cortot, Denis Moro‐Sibilot, Julie Milia, Oliver Gautschi	219
18	Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up breakdown → 2013 ·Annals of Oncology ·Martin Früh, Dirk De Ruysscher, Sanjay Popat, Lucio Crinò, Solange Peters, Enriqueta Felip	458
19	Tobacco-related cancer mortality: projections for different geographical regions in Switzerland 2013 ·Swiss Medical Weekly ·(unknown), S.M. Ess, Harish C. Phuleria, Martin Früh, Matthias Schwenkglenks, H. Frick, T. Cerny, Penelope Vounatsou	3
20	Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non–Small-Cell Lung Cancer 2008 ·Journal of Clinical Oncology ·Martin Früh, Estelle Rolland, Jean‐Pierre Pignon, Lesley Seymour, Keyue Ding, Hélène Tribodet, Timothy Winton, Thierry Le Chevalier, Giorgio V. Scagliotti, Jean-Yves Douillard, Stephen Spiro, Frances A. Shepherd	132

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact